Recognition and processing of cisplatin- and oxaliplatin-DNA adducts

Critical Reviews in Oncology/Hematology

Volumn 53, Issue 1, 2005, Pages 3-11

  Chaney, Stephen G ^a   Campbell, Sharon L ^a   Bassett, Ekaterina ^a   Wu, Yibing ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cisplatin; DNA polymerase; NMR; Oxaliplatin; Platinum

Indexed keywords

CELL PROTEIN; CISPLATIN; DNA DIRECTED DNA POLYMERASE BETA; DNA POLYMERASE; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; DNA ADDUCT; DNA DRUG COMPLEX; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; MISMATCH REPAIR; MUTAGENIC ACTIVITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; REVIEW;

BASE PAIR MISMATCH; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DNA REPLICATION; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 10644245994     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.08.008     Document Type: Review

References (109)

1. M.H. Greene Is cisplatin a human carcinogen J Nat Cancer Inst 84 1992 306 312
2. Sanderson BJS, L.R. Ferguson, and W.A. Denny Mutagenic and carcinogenic properties of platinum-based anticancer drugs Mutat Res-Fundam Mol Mech Mut 355 1996 59 70
3. S.W. Johnson, R.F. Ozols, and T.C. Hamilton Mechanisms of drug resistance in ovarian cancer Cancer 71 1993 644 649
4. B.T. Hill Drug resistance: an overview of the current state of the art Int J Oncol 9 1996 197 203
5. M. Kartalou, and J.M. Essigmann Mechanisms of resistance to cisplatin Mutat Res 478 2001 23 43
6. S.G. Chaney, and A. Vaisman Specificity of platinum-DNA adduct repair J Inorgan Biochem 77 1999 71 81
7. O. Rixe, W. Ortuzar, and M. Alvarez Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem Pharmacol 52 1996 1855 1865
8. Y. Kidani Oxaliplatin Drugs Future 14 1989 529 532
9. W.R. Leopold, R.P. Batzinger, E.C. Miller, J.A. Miller, and R.H. Earhardt Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane Cancer Res 41 1981 4368 4377
10. J.D. Page, I. Husain, A. Sancar, and S.G. Chaney Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality Biochemistry 29 1990 1016 1024
11. M.M. Jennerwein, A. Eastman, and A.R. Khokhar Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes Chem-Biol Interact 70 1989 39 49
12. J.M. Woynarowski, W.G. Chapman, C. Napier, M.C.S. Herzig, and P. Juniewicz Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA Mol Pharmacol 54 1998 770 777
13. A. Eastman The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes Pharmacol Ther 34 1987 155 166
14. J.A. Simon, P. Szankasi, and D.K. Nguyen Differential toxicities of anticancer agents among DNA repair and chaeckpoint mutants of Saccharomyces cerevisiae Cancer Res 60 2000 328 333
15. V. Beljanski, L.G. Marzilli, and P.W. Doetsch DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs Mol Pharmacol 65 2004 1496 1506
16. H.I. Wu, J.A. Brown, M.J. Dorie, L. Lazzeroni, and J.M. Brown Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C Cancer Res 64 2004 3940 3948
17. R.C. van Waardenburg, L.A. de Jong, and F. van Delft Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons Mol Cancer Ther 3 2004 393 402
18. G. Chipitsyna, D. Slonina, and K. Siddiqui HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51 gene expression Oncogene 23 2004 2664 2671
19. S. Aebi, B. Kurdihaidar, and R. Gordon Loss of DNA mismatch repair in acquired resistance to cisplatin Cancer Res 56 1996 3087 3090
20. D. Fink, S. Nebel, and S. Aebi The role of mismatch repair in platinum drug resistance Cancer Res 56 1996 4881 4886
21. D. Fink, H. Zheng, and S. Nebel In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair Cancer Res 57 1997 1841 1845
22. J.T. Drummond, A. Anthoney, R. Brown, and P. Modrich Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line J Biol Chem 271 1996 19645 19648
23. Q. He, C.H. Liang, and S.J. Lippard Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin Proceedings of the National Academy of Sciences of the United States of America vol. 97 2000 5768 5772
24. J.T. Reardon, A. Vaisman, S.G. Chaney, and A. Sancar Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-amine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res 59 1999 3968 3971
25. G.R. Gibbons, J.D. Page, S.K. Mauldin, I. Husain, and S.G. Chaney Role of carrier ligand in platinum resistance in L1210 cells Cancer Res 50 1990 6497 6501
26. W. Schmidt, and S.G. Chaney Role of carrier ligand in platinum resistance of human carcinoma cell lines Cancer Res 53 1993 799 805
27. L.N. Petersen, E.L. Mamenta, T. Stevsner, S.G. Chaney, and V.A. Bohr Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity Carcinogenesis 17 1996 2597 2602
28. A. Nehme, R. Baskaran, and S. Aebi Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin Cancer Res 57 1997 3253 3257
29. A. Nehme, R. Baskaran, and S. Nebel Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells Br J Cancer 79 1999 1104 1110
30. A. Vaisman, M. Varchenko, and A. Umar The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts Cancer Res 58 1998 3579 3585
31. Z.Z. Zdraveski, J.A. Mello, C.K. Farinelli, J.M. Essigmann, and M.G. Marinus MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA J Biol Chem 277 2002 1255 1260
32. G. Strathdee, M.J. MacKean, M. Illand, and R. Brown A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer Oncogene 18 1999 2335 2341
33. D. Mu, M. Tursun, D.R. Duckett, J.T. Drummond, P. Modrich, and A. Sancar Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems Mol Cell Biol 17 1997 760 769
34. M. Yamada, E. Oregan, R. Brown, and P. Karran Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins Nucleic Acids Res 25 1997 491 495
35. L. Fourrier, P. Brooks, and J.M. Malinge Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein J Biol Chem 278 2003 21267 21275
36. X.J. Lin, and S.B. Howell Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin Mol Pharmacol 56 1999 390 395
37. X.J. Lin, H.K. Kim, and S.B. Howell The role of DNA mismatch repair in cisplatin mutagenicity J Inorgan Biochem 77 1999 89 93
38. J.G. de Boer, and B.W. Glickman Mutations recovered in the Chinese Hamster aprt gene after exposure to carboplatin: a comparison with cisplatin Carcinogenesis 13 1992 15 17
39. G.J. Bubley, B.P. Ashburner, and B.A. Teicher Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells Mol Carcinogen 4 1991 397 406
40. D. Burnouf, M. Daune, and R.P.P. Fuchs Spectrum of cisplatin-induced mutations in Escherichia coli Proc Natl Acad Sci USA 84 1987 3758 3762
41. J.G. de Boer, and B.W. Glickman Sequence specificity of mutations induced by the antitumor drug cisplatin in the CHO aprt gene Carcinogenesis 10 1989 1363 1367
42. H.J. Mackay, D. Cameron, and M. Rahilly Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival J Clin Oncol 18 2000 87 93
43. K. Kishi, Y. Doki, and M. Yano Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers Clin Cancer Res 9 2003 4368 4375
44. G. Samimi, D. Fink, and N.M. Varki Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum-based chemotherapy Clin Cancer Res 6 2000 1415 1421
45. M. Scartozzi, M. De Nictolis, and E. Galizia Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients Eur J Cancer 39 2003 1144 1149
46. P.M. Pil, and S.J. Lippard Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin Science 256 1992 234 237
47. C.S. Chow, J.P. Whitehead, and S.J. Lippard HMG domain proteins induce sharp bends in cisplatin- modified DNA Biochemistry 33 1994 15124 15130
48. V.E. Velculescu, and W.S. Eldeiry Biological and clinical importance of the p53 tumor suppressor gene Clin Chem 42 1996 858 868
49. M. Wei, S.M. Cohen, A.P. Silverman, and S.J. Lippard Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins J Biol Chem 276 2001 38774 38780
50. K. Mclaughlin, G. Coren, J. Masters, and R. Brown Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines Int J Cancer 53 1993 662 666
51. D.L. Lawrence, B.N. Engelsberg, R.S. Farid, E.N. Hughes, and P.C. Billings Localization of the binding region of high mobility group protein-2 to cisplatin-damaged DNA J Biol Chem 268 1993 23940 23945
52. S.J. Brown, P.J. Kellett, and S.J. Lippard Ixr1 a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin Science 261 1993 603 605
53. M.M. Mcanulty, J.P. Whitehead, and S.J. Lippard Binding of Ixr1, a yeast HMG-domain protein, to cisplatin- DNA adducts in vitro and in vivo Biochemistry 35 1996 6089 6099
54. M.M. Mcanulty, and S.J. Lippard The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast Mutat Res-DNA Repair 362 1996 75 86
55. U.M. Ohndorf, J.P. Whitehead, N.L. Raju, and S.J. Lippard Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts Biochemistry 36 1997 14807 14815
56. E.E. Trimmer, D.B. Zamble, S.J. Lippard, and J.M. Essigmann Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities Biochemistry 37 1998 352 362
57. D.K. Treiber, X.Q. Zhai, H.M. Jantzen, and J.M. Essigmann Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor) Proc Natl Acad Sci USA 91 1994 5672 5676
58. X. Zhai, H. Beckmann, H-M. Jantzen, and J.M. Essigmann Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor Biochemistry 37 1998 16307 16315
59. P. Vichi, F. Coin, and J.P. Renaud Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP EMBO J 16 1997 7444 7456
60. S.M. Cohen, E.R. Jamieson, and S.J. Lippard Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 12-cross-links Biochemistry 39 2000 8259 8265
61. Y. Jung, Y. Mikata, and S.J. Lippard Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA J Biol Chem 276 2001 43589 43596
62. J. Yaneva, S.H. Leuba, K. Vanholde, and J. Zlatanova The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA Proc Natl Acad Sci USA 94 1997 13448 13451
63. C.C. Wetzel, and S.J. Berberich DNA binding activities of p53 protein following cisplatin damage of ovarian cells Oncol Res 10 1998 151 161
64. C.C. Wetzel, and S.J. Berberich p53 binds to cisplatin-damaged DNA Biochim et Biophys Acta-Gene Struct Express 1517 2001 392 397
65. G. Chu, and E. Chang Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA Science 242 1988 564 567
66. A. Payne, and G. Chu Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage Mutat Res-Fundam Mol Mech Mut 310 1994 89 102
67. J.J. Turchi, and K. Henkels Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase J Biol Chem 271 1996 13861 13867
68. C.J. Jones, and R.D. Wood Preferential binding of the Xeroderma-Pigmentosum group-A complementing protein to damaged DNA Biochemistry 32 1993 12096 12104
69. C.K. Clugston, K. Mclaughlin, M.K. Kenny, and R. Brown Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis- diamminedichloroplatinum (II) Cancer Res 52 1992 6375 6379
70. S.M. Patrick, and J.J. Turchi Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro Biochemistry 37 1998 8808 8815
71. S.M. Patrick, and J.J. Turchi Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA J Biol Chem 274 1999 14972 14978
72. E.R. Jamieson, and S.J. Lippard Structure, recognition, and processing of cisplatin-DNA adducts Chem Rev 99 1999 2467 2498
73. J.C. Huang, D.B. Zamble, J.T. Reardon, S.J. Lippard, and A. Sancar HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease Proc Natl Acad Sci USA 91 1994 10394 10398
74. J.S. Hoffmann, D. Locker, G. Viliani, and M. Leng HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts J Mol Biol 270 1997 539 543
75. A. Vaisman, S.E. Lim, and S.M. Patrick Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts Biochemistry 38 1999 11026 11039
76. D.B. Zamble, Y. Mikata, C.H. Eng, K.E. Sandman, and S.J. Lippard Testis-specific HMG-domain protein alters the responses of cells to cisplatin J Inorg Biochem 91 2002 451 462
77. M. Wei, O. Burenkova, and S.J. Lippard Cisplatin sensitivity in Hmbg1-/- and Hmbg1+/+ mouse cells J Biol Chem 278 2003 1769 1773
78. F. Coin, P. Frit, B. Viollet, B. Salles, and J.M. Egly TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease Mol Cell Biol 18 1998 3907 3914
79. E. Bassett, A. Vaisman, J.M. Havener, C. Masutani, F. Hanaoka, and S.G. Chaney Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro Biochemistry 42 2003 14197 14206
80. A. Vaisman, C. Masutani, F. Hanaoka, and S.G. Chaney Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta Biochemistry 39 2000 4575 4580
81. A. Vaisman, and S.G. Chaney The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta J Biol Chem 275 2000 13017 13025
82. J.M. Havener, S.A. McElhinny, E. Bassett, M. Gauger, D.A. Ramsden, and S.G. Chaney Translesion synthesis past platinum DNA adducts by human DNA polymerase mu Biochemistry 42 2003 1777 1788
83. E. Bassett, A. Vaisman, and K.A. Tropea Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta DNA Repair (Amst) 1 2002 1003 1016
84. A. Vaisman, M.W. Warren, and S.G. Chaney The effect of DNA structure on the catalytic efficiency and fidelity of human DNA polymerase beta on templates with platinum-DNA adducts J Biol Chem 276 2001 18999 19005
85. A. Bresson, and R.P. Fuchs Lesion bypass in yeast cells: Pol eta participates in a multi-DNA polymerase process EMBO J 21 2002 3881 3887
86. L. Haracska, S. Prakash, and L. Prakash Yeast DNA polymerase zeta is an efficient extender of primer ends opposite from 78-dihydro-8-Oxoguanine and O6-methylguanine Mol Cell Biol 23 2003 1453 1459
87. R.E. Johnson, M.T. Washington, L. Haracska, S. Prakash, and L. Prakash Eukaryotic polymerases τ and ζ act sequentially to bypass DNA lesions Nature 406 2000 1015 1019
88. C. Masutani, R. Kusumoto, S. Iwai, and F. Hanaoka Mechanisms of accurate translesion synthesis by human DNA polymerase eta EMBO J 19 2000 3100 3109
89. R. Kusumoto, C. Masutani, S. Iwai, and F. Hanaoka Translesion synthesis by human DNA polymerase eta across thymine glycol lesions Biochemistry 41 2002 6090 6099
90. R.E. Johnson, M.T. Washington, S. Prakash, and L. Prakash Fidelity of human DNA polymerase η J Biol Chem 275 2000 7447 7450
91. M.T. Washington, R.E. Johnson, L. Prakash, and S. Prakash Accuracy of lesion bypass by yeast and human DNA polymerase η Proc Natl Acad Sci USA 98 2001 8355 8360
92. T. Matsuda, K. Bebenek, C. Masutani, F. Hanaoka, and T.A. Kunkel Low fidelity DNA synthesis by human DNA polymerase-eta Nature 404 2000 1011 1013
93. V.M. Maher, L.M. Ouellette, R.D. Curren, and J.J. McCormick Frequency of ultraviolet light-induced mutations is higher in xeroderma pigmentosum variant cells than in normal human cells Nature 261 1976 593 595
94. M. Cordeiro-Stone, J.C. Boyer, B.A. Smith, and W.K. Kaufmann Xeroderma pigmentosum variant and normal fibroblasts show the same response to the inhibition of DNA replication by benzo[a]pyrene-diol-epoxide-I Carcinogenesis 7 1986 1783 1786
95. V. Bergoglio, Y. Canitrot, and L. Hogarth Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents Oncogene 20 2001 6181 6187
96. Y. Canitrot, C. Cazaux, and M. Frechet Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs Proc Natl Acad Sci USA 95 1998 12586 12590
97. E. Bassett, N.M. King, M.F. Bryant, S. Hector, L. Pendyala, S.G. Chaney, and M. Cordeiro-Stone The role of DNA polymerase η in translesion synthesis past platinum-DNA adducts in human fibroblasts Cancer Res. 64 2004 6469 6475
98. X. Lin, and S.B. Howell The role of DNA polymerase zeta in cisplatin resistance Proc Am Assoc Cancer Res 43 2002 425
99. P.M. Takahara, C.A. Frederick, and S.J. Lippard Crystal structure of the anticancer drug cisplatin bound to duplex DNA J Am Chem Soc 118 1996 12309 12321
100. B. Spingler, D.A. Whittington, and S.J. Lippard 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex Inorg Chem 40 2001 5596 5602
101. M.H. Lamers, A. Perrakis, J.H. Enzlin, H.H.K. Winterwerp, N. de Wind, and T.K. Sixma The crystal structure of DNA mismatch repair protein MutS binding to a G center dot T mismatch Nature 407 2000 711 717
102. G. Obmolova, C. Ban, P. Hsieh, and W. Yang Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA Nature 407 2000 703 710
103. U.M. Ohndorf, M.A. Rould, Q. He, C.O. Pabo, and S.J. Lippard Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins Nature 399 1999 708 712
104. M.R. Sawaya, R. Prasad, S.H. Wilson, J. Kraut, and H. Pelletier Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism Biochemistry 36 1997 11205 11215
105. Y. Wu, P. Pradhan, J. Havener, G. Boysen, J.A. Swenberg, S.L. Campbell, and S.G. Chaney NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex J Mol Biol. 341 2004 1251 1269
106. L.G. Marzilli, J.S. Saad, Z. Kuklenyik, K.A. Keating, and Y. Xu Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA J Am Chem Soc 123 2001 2764 2770
107. A. Gelasco, and S.J. Lippard NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) dGpG intrastrand cross-link, the major adduct of the anticancer drug cisplatin Biochemistry 37 1998 9230 9239
108. A. Travers Recognition of distorted DNA structures by HMG domains Curr Opinion Struct Biol 10 2000 102 109
109. Y. Zhang, X. Wu, D. Guo, O. Rechkoblit, N.E. Geacintov, and Z. Wang Two-step error-prone bypass of the (+)- and (-)-trans-anti-BPDE-N(2)-dG adducts by human DNA polymerases eta and kappa Mutat Res 510 2002 23 35